Whilst trend wise it's obviously only going one way I think we may find a bottom here .
So my risk reward view of staying short is less interesting to me now . From the mid 40s to 12.8p . It's been a good trend to be on , though I wish I had spotted it earlier in 2015 . If anyone is still short just look at using the 50 sma as your stop plus or minus a % tolerance . IMO
If this bases and finds support who knows I may return as a bull next time . I do love these charts
"Total revenues are expected to be ahead of current market expectations, principally as a result of larger than expected research collaboration milestones, already announced to the market. With better than expected total operating costs due to careful cost control, the resulting operating loss is expected to be smaller than consensus."
Goes on to say Tuzistra sales are up 200% to 35,000 prescriptions (FY 2016 = 11,000) ... More a reflection of the low base rather than sales improvement.
Full year report in September should be rather interesting.
This article breaks down the RNS well:
Lurking on these beautiful trending stocks you can bet is where you can find me ! Its all I look out for 24/7 !! Just need the time to find more .
These pharma stocks remind me of mining explorers ! once they reach peak euphoria the only way is usually down as time frames and chances of success are usually either over exaggerated or the timeframes too optimistic. Sadly the processes involved suck up loads of cash and investors with short time frames exit .
All these Pharma and their equivalent mining explorers work in the same way .
Sadly as I think these firms should be supported. But am a speculator after all.
Read Edison's note on VERNALIS, out this morning, by visiting https://www.research-tree.com/company/GB00B3Y5L754
"Vernalis intends to raise £40m (gross) through the issue of 80m new shares at 50p per share. This equity raise will remove any uncertainty over whether Vernaliss cash position is sufficient to take it through to sustainable profitability in FY18 (on our current forecasts). New funds will be used to boost existing working capital required for a conservative Tuzistra XR roll-out, upcoming Moxatag re-launch and future launches of the remaining four US cough cold programmes in development with Tris. The share placing is on a non pre-emptive basis and is conditional on being passed at the General Meeting scheduled on 12 May 2016 ..."
Read Edisons note on Vernalis (VER), out this morning, by visiting www.research-tree.com
Vernalis reported a modest £0.6m in Tuzistra XR sales over the first four months post-launch due to the mild cough cold season. The US launch of this prescription-only (Rx), extended release (ER) cough cold medicine is the first step in Vernaliss transition into a commercial-stage speciality pharma company, targeting a $3.5bn market opportunity. The emphasis for year one of Tuzistra XR commercialisation is...
Vernalis plc today announces successful completion of the second and final CCP-01 pivotal comparative bioavailability study. This positive multi-dose study follows successful completion of the single dose study announced in November last year.
Looks good news.
CCP-01 is the first product being developed for Vernalis by Tris Pharma for the US prescription cough cold market. Both pivotal comparative bioavailability studies required to support an NDA filing in mid-2014 have now been completed successfully. In addition to these studies, the NDA will be supported by data from a 12-month stability programme for which positive interim 6-month stability data has already been generated.
Under the deal announced in February 2012, Vernalis is paying Tris Pharma to develop up to six unique extended release equivalents to existing immediate release prescription cough cold treatments. The financial terms of this licensing deal have not been disclosed.
Ian Garland, CEO of Vernalis commented We are delighted with these further positive results that complete the critical clinical component of the mid-2014 NDA filing. We look forward to completion of the on-going stability study and the filing of our first NDA from our collaboration with Tris
Vernalis plc (LON:VER)s stock had its buy rating restated by analysts at N+1 Singer in a research report issued to clientsand investors on Monday, AnalystRatings.NET reports. They currently have a GBX 43 ($0.72) price target on the stock. N+1 Singers target price suggests a potential upside of 21.13% from the stocks previous close.
Separately, analysts at Nplus1 Brewin initiated coverage on shares of Vernalis plc in a research note on Wednesday, January 29th. They set a buy rating and a GBX 43 ($0.72) price target on the stock.
Shares of Vernalis plc (LON:VER) opened at 35.50 on Monday. Vernalis plc has a 52-week low of GBX 18.75 and a 52-week high of GBX 38.00. The stock has a 50-day moving average of GBX 36.05 and a 200-day moving average of GBX 31.10.
For now the shares are on the up and MM continue to have little stock. The price dropped today to create some sells but there are none as the company looks to be in very good shape. Chances are 40p+ so enjoy the ride if it happens.
There has always been some potential with this share, but until all the drugs still working their way through trials actually make it to production, then they all could turn out to be money poured down the drain. For those of us who have held this share for many years we remember all the times potential good drugs have failed to deliver as I said the upside is greater than the down but researching into new drugs is always a bit of a gamble. The company has gone back to the shareholders for more money too many times to be too confident of future performance.
"we are not out of the woods yet with this share"
What do you see as an issue? Revenues grew 29% to £7.6m for the six months to June 2013. But key is Frovatriptan had seen an 34% increase in sales to £2.6m during those 6 months. NDA filing on the next drug and with 80 million in the bank the numbers and success indicates a potential *future* cash cow.
I suspect growth in Frovatriptan will be key to proving this and it is only recently proved to be more efficient in combination... and growth should come from this combination.
I will chat to myself... but the feeling is that the buyer wants more shares. I think the company is great but not being an expert on phama/biotecs I don't claim to understand its full potential other than look what other companies buy drugs at for Phase III and beyond often Â£200m a drug. Currently VER have a loot of these drugs that could get to this criteria. Current value of VER just Â£160m and much of that is cash (about Â£80m).
Vernalis Initiates Phase Ib/II Proof-of-Concept Study with V81444
12 July 2013
Vernalis plc today announces that it has dosed the first subjects in a Phase Ib/II proof-of-concept (PoC) study of V81444, an A2A antagonist which has potential applications for the treatment of Parkinsons disease and other disorders of the central nervous system (CNS).
The randomised, double-blind, placebo controlled study will evaluate the safety, tolerability and pharmacokinetics of V81444 after twice daily administration for 14 days in 24 subjects. As the study is being conducted in subjects with a confirmed diagnosis of one of the potential indications, the aim is also to provide initial proof-of-concept for use of V81444 as a potential treatment for this CNS indication. The trial is being conducted at a single US site under an approved Investigational New Drug (IND) application.
The Food and Drug Administration plans to loosen rules for approving new treatments for Alzheimer's disease. Drugs would be approved if people at very early stages of the disease subtly improved their performance on memory or reasoning tests, even before developing impairments. Firms would not have to show drugs improved daily functioning.
Interesting press release particularly as Vernalis hold World wide rights and are not in collaboration with anyone else on this one.
12 December 2012
Vernalis plc today announces successful results from a Receptor Occupancy (RO) study with V81444, its A2A antagonist which has potential applications in Parkinsons disease and other CNS indications.
The RO study examined the relationship between dose, plasma concentration and blockade of the A2A receptor using positron emission tomography (PET) scanning and included a preliminary evaluation, using functional MRI (fMRI), of the effects of V81444 on cognitive function.
The RO study demonstrated that full A2A blockade could be achieved with single doses that were within the range of doses previously shown to be well tolerated with no safety concerns. The RO study has provided confirmation of the appropriate dose to be used in the forthcoming clinical proof-of-concept trial.
Vernalis now plans to initiate, in the first half of next year, a Phase IIa proof-of-concept study to further evaluate the pharmacokinetics, safety and tolerability of V81444 in patients, together with an evaluation of efficacy in a target patient population.
Ian Garland, CEO of Vernalis commented We are very pleased with these results and are already actively preparing for the continued development of this exciting program over the next 12 months.
3 months ago directors decided to effectively make VER an investment vehicle concentrating on coughs & colds raising £80m of new funds. VER was ticking along nicely without the need for more funds so existing shareholders suffered massive dilution due to this change in strategy. Ok, they wanted to utilise VERs massive tax losses although it will still take 3-5 years before any products go on sale.
Today the CEO & FD effectively give themselves 2% of VER at a 96% discount. I was under the impression they were paid reasonably large salaries and had existing share options. The previous share options were worthless because management failed to create shareholder value, so they give themselves more options virtually guaranteed to make money.
The move to AIM is becoming all too clear, absolutely zero corporate governance and contempt for shareholders.
Important message from the Financial Conduct Authority:
Posting inside information that is not public knowledge, or information that is false or misleading, may constitute market abuse.
This could lead to an unlimited fine and up to seven years in prison.
If you have any information, concerns or queries about market abuse, click here.
The content of the messages posted represents the opinions of the author, and does not represent the opinions of Interactive Investor Trading Limited or its affiliates and has not been approved or issued by Interactive Investor Trading Limited.
You should be aware that the other participants of the above discussion group are strangers to you and may make statements which may be misleading, deceptive or wrong.
Please remember that the value of investments or income from them may go down as well as up and that the past performance of an investment is not a guide to its performance in the future.
The discussion boards on this site are intended to be an information sharing forum and is not intended to address your particular requirements.
Whilst information provided on them can help with your investment research you need to consider carefully whether you should make (or refraining from making) investment or other decisions based on what you see without doing further research on investments you are interested in.
Participating in this forum cannot be a substitute for obtaining advice from an appropriate expert independent adviser who takes into account your circumstances and specific investment needs in selected investments that are appropriate for you.